Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Plumbs Data's Depths To Differentiate CDK4/6 Inhibitor Verzenio

Executive Summary

Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.

You may also be interested in...



Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)

The latest drug development news and highlights from our US FDA Performance Tracker.

JUNIPER Disappoints But Lilly Continues With Abemaciclib In Different Combos, Cancers

Lilly's top-line Phase III JUNIPER data for abemaciclib in KRAS-mutated advanced non-small cell lung cancer may have disappointed, but the big pharma has vowed to continue evaluating the agent in this and in other cancers, and in combination therapies.

Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?

Lilly reported positive top-line results for abemaciclib in the Phase III MONARCH 2 trial and revealed a regulatory strategy that has it rapidly racing after competing CDK4/6 inhibitors already approved for certain breast cancer patients.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel